Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Genetic Findings of Potential Donor Origin following Hematopoietic Cell Transplantation: Recommendations on Donor Disclosure and Genetic Testing from the World Marrow Donor Association (WMDA)
Allogeneic hematopoietic cell transplantation (HCT) is a well-established treatment for various hematological conditions, where cure or disease control is unlikely to be achieved through other forms of therapy alone.1 The cornerstone is a stem-cell donation, sourced from an appropriately HLA matched donor, in the form of HLA-identical sibling, matched unrelated, cord or mismatched related donor.2 Whilst an HLA-identical sibling is generally considered the preferred donor, this is available to fewer than a third of patients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 4, 2023 Category: Hematology Authors: A Pryce, Eerden E Van, M Cody, J Oakes, A DeSalvo, S Bannon, C Burlton, R Pawson, W Fingrut, F Barriga, J Ward, C Ingram, M Walsh, K El-Ghariani, S Ocheni, L Machin, D Allan, T Mengling, C Anthias Source Type: research
Non-GVHD enterocolitis following cord blood transplant is real, with poorly understood pathophysiology, and requires distinct management from GVHD, with eventual resolution without immune suppression
Cord blood transplant (CBT) has specific utility in haematopoietic stem cell transplant (HSCT) for both malignant and non-malignant diseases (NMD). In malignant disease, we have shown that CBT reduces relapse and improves leukaemia free survival compared with other cell sources1 and this, together with the rapid availability of cord blood units for immediate use, makes it a particularly attractive stem cell source in the refractory disease setting2. Furthermore, the superior chimerism achieved after CBT, compared with other donor sources,3, 4 improves long-term disease outcomes in NMD5. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 3, 2023 Category: Hematology Authors: Claire Horgan, Stefania Bitetti, Melanie Newbould, Chitra Sethuraman, Andrew Fagbemi, Adnan Kala, Nicola Williams, Robert Wynn Source Type: research
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplants for patients with Hodgkin lymphoma: a comparative study of the LWP EBMT.
Post-transplant cyclophosphamide (PTCy) has proven to be a highly effective strategy in preventing graft-versus-host disease (GVHD) in haploidentical hematopoietic stem cell transplantation (HSCT), but it is being increasingly used in HLA-matched transplants1 –9. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - December 1, 2023 Category: Hematology Authors: J Montoro, A Boumendil, H Finel, S Bramanti, L Castagna, D Blaise, A Dominietto, A Kulagin, I Yakoub-Agha, A Tbakhi, C Solano, S Giebel, Z Gulbas, L L ópez Corral, J.A Pérez-Simón, J.L Díez Martín, J Sanz, L Farina, Y Koc, G Socié, M Arat, M Jurado, Source Type: research
Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations
The successful use of post-transplant cyclophosphamide (PTCY) in allogeneic hematopoietic cell transplantation (allo-HCT) performed from haploidentical donors1-3, encouraged the progressive utilization of PTCY for GVHD prevention into allo-HCT performed from HLA-matched donors, also with notable success4-8. However, the use of PTCY has also been associated with non-desired outcomes such as delayed engraftment, higher risk of infections, and specific organ toxicities such as cardiac complications, which raises the question of whether this prophylaxis should be universalized or not9-11. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 30, 2023 Category: Hematology Authors: Mar ía Queralt Salas, Alexandra Pedraza, Paola Charry, María Suárez-Lledó, Luis Gerardo Rodríguez-Lobato, Marc Brusosa, María Teresa Solano, Anna Serrahima, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Jordi Arcarons, Noemi de Llobet, Laura Rosiñol Source Type: research
Ex vivo-expanded cord blood nk cells combined with rituximab and high-dose chemotherapy and autologous sct for b-nhl
Following decades of treating patients with relapsed B-cell non-Hodgkin lymphomas (NHL) with high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT), tumor relapse remains the major cause of treatment failure.1 While autologous CAR-T cells have recently shown improved outcomes compared to HDC/ASCT in refractory or poor-risk relapsed DLBCL,2, 3 more than 50% of patients still relapse after CAR-T and most of them face a dismal prognosis.4, 5 HDC/ASCT could still be useful for these patients if its antitumor efficacy were increased. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 30, 2023 Category: Hematology Authors: Yago Nieto, Pinaki Banerjee, Indresh Kaur, Kun Hee Kim, Dexing Fang, Peter F Thall, Lori Griffin, Melissa Barnett, Rafet Basar, Chitra Hosing, Jeremy Ramdial, Samer Srour, May Daher, David Marin, Xianli Jiang, Ken Chen, Richard Champlin, Elizabeth J Shpal Source Type: research
A Reflection Inspired by Reflections
In 2001, these diametrically different comments came to our Long-Term Follow-up Program in response to an annual questionnaire sent to patients surviving after hematopoietic cell transplantation (HCT). The last item in the questionnaire invites respondents to tell us anything they want us to know about their health and well-being. From the inspiring, yet emotionally searing experience of reviewing the comments during the first few years, I realized that sharing them with others would help the community more widely. Selected comments, or reflections if you will, were anonymized and assembled as an anthology each year. ...
Source: Biology of Blood and Marrow Transplantation - November 29, 2023 Category: Hematology Authors: Paul J. Martin Tags: Reflections Source Type: research
Long-term Survivors and Failures of CAR-T Therapy for Lymphoma: Is there a Role for Allogeneic Transplantation After the CAR-T Crash?
In this issue of Transplantation and Cellular Therapy, Derigs, et al. report outcomes of diffuse large B-cell lymphoma (DLBCL) patients who progressed after chimeric antigen receptor T cell (CAR-T) therapy with a focus on long-term survivors and the role of allogeneic hematopoietic cell transplantation (HCT) following disease progression . (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 29, 2023 Category: Hematology Authors: Michael A. Spinner, Krishna V. Komanduri Tags: The Bottom Line Source Type: research
The Role of Autologous Stem Cell Transplant in Ultra-High-Risk Myeloma: Do the Ends Still Justify the Means?
The first well-documented case of multiple myeloma (MM) was by Samuell Solly in 1844 . While the field continues to advance at a pace previously unimaginable, some questions still linger over 175 years later. For instance, the topic of what defines high-risk MM (HRMM) continues to elicit debate. The advent and large-scale availability of fluorescence in situ hybridization (FISH) technology has led to better detection of cytogenetic abnormalities and the ability to correlate these abnormalities with outcomes. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 29, 2023 Category: Hematology Authors: Barry Paul Tags: The Bottom Line Source Type: research
Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry
Background: There is a limited body of evidence for Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HSCT) in older patients. Previous studies have used a high proportion of bone marrow derived grafts and a variety of conditioning regimens. In Australia and New Zealand, Haplo-HCST is predominantly performed using peripheral blood (PB) with universal use of post-transplant cyclophosphamide (PTCy).Objective: To characterize the outcomes of older recipients undergoing Haplo-HSCT for Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndromes (MDS). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 26, 2023 Category: Hematology Authors: Edward Abadir, Jad Othman, John Kwan, David J Gottlieb, Glen A Kennedy, Ashish Bajel, Richard Doocey, Travis Perera, Anne-Marie Watson, Peter G Bardy, Matthew Greenwood, David J. Curtis, Steven Tran, John Moore, Nada Hamad Source Type: research
Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
Abstract (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 23, 2023 Category: Hematology Authors: Christine Robin, Catherine Cordonnier, Gloria Tridello, Nina Knelange, Alienor Xhaard, Sylvain Chantepie, Aline Tanguy-Schmidt, Harry C Schouten, Moshe Yesherun, Vanderson Rocha, Micha Srour, Nicolaus Kr öger, Marie-Pierre Ledoux, Jakob Dalgaard, Anne Th Source Type: research
Easix score correlates with endothelial dysfunction biomarkers and predicts risk of acute graft-versus-host disease after allogeneic transplantation
Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Diagnosis of acute GVHD (aGVHD) is based on clinical features, patient symptoms, laboratory values and, in most cases, histological confirmation. In recent years, efforts have been made to identify potential non-invasive peripheral blood biomarkers with diagnostic and clinical value in aGVHD, and some promising results have been achieved with markers related to endothelial damage [1 –3]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 22, 2023 Category: Hematology Authors: Alexandra Pedraza, Mar ía Queralt Salas, Luis Gerardo Rodríguez-Lobato, Silvia Escribano-Serrat, María Suárez-Lledo, Nuria Martínez-Cebrian, María Teresa Solano, Jordi Arcarons, Laura Rosiñol, Gonzalo Gutiérrez-García, Francesc Fernández-Avilés Source Type: research